Carli P M, Coebergh J W, Verdecchia A
Registry of Haematological Malignancies in Cöte d'Or, Dijon, France.
Eur J Cancer. 1998 Dec;34(14 Spec No):2253-63. doi: 10.1016/s0959-8049(98)00339-6.
Data on 73,070 patients for seven major haematological malignancies diagnosed in Europe between 1985 and 1989 from 39 population-based cancer registries in 17 countries are included in the EUROCARE database. Relative survival was analysed by country and age between 1985 and 1989 and time trends were analysed from 1978-1989 for 13 countries which collaborated in EUROCARE for this entire period. The European weighted age-standardised 5-year relative survival rate was 72% for patients with Hodgkin's disease (HD, ranging from 45 to 76% in 13 countries), 63% for chronic lymphocytic leukaemia (CLL, range 51-79%, 14 countries), 46% for patients with non-Hodgkin's lymphoma (NHL, range 25-63%, 17 countries), 31% for patients with chronic myelocytic leukaemia (CML, range 8-40%, 13 countries), 28% for patients with multiple myeloma (MM, range 18-36%, 14 countries), 25% for patients with acute lymphoblastic leukaemia (ALL, range 19-33%, 7 countries) and 10% for patients with acute myeloblastic leukaemia (AML, range 4-15%, 11 countries). In all countries, relative survival declined with age, most markedly for patients with acute leukaemias. Patients in Northern and Western Europe had better survival rates, particularly in younger patients (15-45 years of age), whilst those in Eastern European countries tended to have poorer rates. Compared with 1978-1979, relative 5-year survival improved in 1987-1989 for most haematological malignancies (relative risk (RR) of death for CLL 0.65, AML 0.75, HD 0.76, ALL 0.79, NHL 0.82), with only CML (RR 0.95) and MM (RR 1.00) showing little or no change. These results suggest that generally and particularly in Eastern Europe there is room for improvement in the diagnosis and treatment of haematological malignancies. The intercountry differences also highlight the importance of socio-economic conditions to health status.
欧洲癌症研究与治疗组织（EUROCARE）数据库纳入了1985年至1989年间欧洲17个国家39个基于人群的癌症登记处诊断的73070例7种主要血液系统恶性肿瘤患者的数据。分析了1985年至1989年间按国家和年龄划分的相对生存率，并对1978 - 1989年间在EUROCARE整个期间合作的13个国家的时间趋势进行了分析。霍奇金淋巴瘤（HD）患者的欧洲加权年龄标准化5年相对生存率为72%（13个国家范围为45%至76%），慢性淋巴细胞白血病（CLL，14个国家，范围51% - 79%）为63%，非霍奇金淋巴瘤（NHL，17个国家，范围25% - 63%）患者为46%，慢性粒细胞白血病（CML，13个国家，范围8% - 40%）患者为31%，多发性骨髓瘤（MM，14个国家，范围18% - 36%）患者为28%，急性淋巴细胞白血病（ALL，7个国家，范围19% - 33%）患者为25%，急性髓细胞白血病（AML，11个国家，范围4% - 15%）患者为10%。在所有国家，相对生存率均随年龄下降，急性白血病患者下降最为明显。北欧和西欧的患者生存率更高，尤其是年轻患者（15 - 45岁），而东欧国家的患者生存率往往较低。与1978 - 1979年相比，1987 - 1989年大多数血液系统恶性肿瘤的5年相对生存率有所提高（CLL死亡相对风险（RR）为0.65，AML为0.75，HD为0.76，ALL为0.79，NHL为0.82），只有CML（RR 0.95）和MM（RR 1.00）变化很小或没有变化。这些结果表明，总体而言，尤其是在东欧，血液系统恶性肿瘤的诊断和治疗仍有改善空间。国家间差异也凸显了社会经济状况对健康状况的重要性。
